Loading stock data…
TRDA
$14.50+1.00 (+7.41%)
Market ClosedLast close May 1
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Entrada Therapeutics, Inc. in the Healthcare sector is trading at $14.50. The stock is currently near its 52-week high of $14.56, remaining 58.1% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why TRDA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.50
Potential Upside
5%
Whystock Fair Value$15.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$499.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.15
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.96%
Volume
Today's trading volume
318,980
Recent News
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index and the State Str
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +290.39% and +11.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +11.26% and +2.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?